BioNTech on Thursday entered into a strategic research collaboration and worldwide licensing agreement with Suzhou-based biotech MediLink Therapeutics to develop next-generation antibody-drug conjugates for cancer.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,